Entera Bio Ltd. Employee Directory

Biotechnology ResearchIsrael11-50 Employees

Entera Bio Ltd. is a clinical-stage biotechnology company based in Israel focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet could transform care. It relies on a proprietary delivery technology, N-Tab, to enable oral administration of peptide therapeutics and maintains a pipeline of five oral programs expected to enter clinical testing from Phase 1 to Phase 3 by 2025. The most advanced candidate, EB613, targets post-menopausal osteoporosis with low bone mineral density and has shown positive Phase 2 results prompting a planned Phase 3 program. 

Beyond EB613, Entera is advancing EB612 for hypoparathyroidism and other oral peptide therapies, including collaborations with OPKO Health for select programs. The company focuses on offering oral alternatives to injections to address adherence and convenience for patients with obesity, malabsorption syndromes, and related metabolic conditions. A recent development includes positive data presented at ESPEN 2025 for an oral GLP-2 tablet addressing short bowel syndrome, developed in collaboration with OPKO.

Sign up for free to view info

Company overview Email format